Stock Analysis
Labcorp Holdings Inc.LH
P/E 25.73×· 5Y range 7.94–56.95×· 52th percentile of history
Sector: Healthcare · Industry: Diagnostics & Research
AnalystsStrong Buy27 analystsP/E 25.7× sits at the 52nd percentile of its 5.086926762491444-year history.
Cash covers 2% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality100
Risks
- Growth25
- Profitability42
Mixed picture — no clear quality or value edge.
Market context
-2.2% today· Z 1.8σ
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
What's happening with LH
Profile
Strong earnings quality; growth and profitability lag behind.
How is each axis scored?
- Valuation61/100 · Moderate
- P/E vs own history (52th pct)12/25
- FCF yield (4.5%)12/25
- P/S (1.8x)25/25
- EV/EBIT (21.7x)12/25
- Growth25/100 · Weak
- Revenue CAGR (-3.5%)0/25
- Net income CAGR (-22.1%)0/25
- EPS CAGR 5Y (-19.1%)0/25
- Fwd implied growth (60.7%)25/25
- Profitability42/100 · Weak
- ROIC (7.7%)5/25
- ROE (11.6%)12/25
- Net margin (7.0%)13/25
- Operating margin (10.4%)12/25
- Financial Health59/100 · Moderate
- Altman Z (2.90)18/25
- Current ratio (1.80)18/25
- Interest coverage (7.2x)18/25
- Net cash / debt (D/A 36%)5/25
- Quality100/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.78)25/25
- FCF conversion (115%)25/25
- Margin stability (σ 5.0%)25/25
- Moat50/100 · Moderate
- ROIC >12% years (2/10 yrs)0/25
- Median gross margin (30.0%)13/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 3.4%)12/25
Risk Flags
- ⚠Revenue shrinking 3.5%/yr
About Labcorp Holdings Inc.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. Show more
The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
Headquarters: BURLINGTON, NC · Employees: 71,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
61BP/E (TTM)25.7xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 7.9x–56.9x · 52nd pct
P/FCF22.8xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.5%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.8%–14.0% · 25th pct
P/S (TTM)1.80xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 5Y history: 1.2x–2.1x · 87th pct
EV/EBIT21.7xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 7.0x–39.1x · 61st pct
EV/Sales2.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E16.0xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.99xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.79D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.91%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio23.9%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
42D+ROIC7.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE11.6%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA5.4%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin7.0%C
Grade C: AverageNet Income / Revenue
Operating Margin10.4%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin28.9%D
Grade D: LowGross Profit / Revenue
FCF Margin8.1%C
Grade C: AverageFCF / Revenue
True FCF Margin7.2%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR-3.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-22.1%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-19.1%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth60.7%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-17.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income12.5%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.9%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
59CAltman Z-Score2.90C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.80xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.25xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage7.2xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment5.8yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT4.5xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.79xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.02xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
100A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.78A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion115.3%A
Grade A: StrongFCF / Net Income
Margin Stability5.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.77xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Vaughn Bryan T Filed | Vaughn Bryan T | Grant / award | +1.5K | |
Meltzer Jonathan C Filed | Meltzer Jonathan C | Grant / award | +900 | |
Oyegunwa Akinbolade Filed | Oyegunwa Akinbolade | Grant / award | +750 | |
Caveney Brian J Filed | Caveney Brian J | Grant / award | +3.0K | |
ANDERSON KERRII B Filed | ANDERSON KERRII B | SellOpen market sale | -3000 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Schechter Adam H Filed | Schechter Adam H | SellOpen market sale | -4669 | |
Summy Amy B. Filed | Summy Amy B. | SellOpen market sale | -924 | |
Wilkinson Peter J Filed | Wilkinson Peter J | Option exercise | -1338 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
50CROIC >12% Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)30.0%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor3.4%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$12.36
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$1.75
Cash & short-term investments per share (Finnhub)
Book Value / Share$106.39
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$6.82B
Total debt obligations (short + long term)
Cash & Equiv.$141.80M
Cash and short-term investments
Net Debt$6.68B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$8.62B
Shareholders' equity (book value)
Asset / Liability1.87xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$25.79B
Current Market Capitalization
Beta0.89B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Labcorp Holdings Inc. (LH)
LH is down 2.19% at the last close. Labcorp Holdings Inc. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.90 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -2.78 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -4%), which weighs on the growth outlook.
- Takes ~5.8 years to repay net debt from free cash flow.
See how LH ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all LH moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 316.52 | -2.63% | -2.15 |
| Oct 15 | After-hours | 325.03 | +2.42% | 2.14 |
| Sep 22 | Pre-market | 301.00 | -6.23% | -4.31 |
| Sep 21 | After-hours | 309.64 | -3.45% | -2.26 |
Frequently Asked Questions about LH
What is the current Labcorp Holdings Inc. (LH) stock price?
LH is trading at $317.95 at the last market close, down 2.19% on the session. PreMarketPrice tracks LH pre-market, intraday and after-hours prices.
Is LH stock a buy right now?
PreMarketPrice's quantitative model rates Labcorp Holdings Inc.'s financial health at 59/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is LH stock overvalued?
Labcorp Holdings Inc. trades at a trailing P/E of 25.7 and our valuation score rates it 61/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Labcorp Holdings Inc. report earnings?
No confirmed earnings date is currently scheduled for LH. The Earnings section lists recent reports and updates as dates are announced.
What sector does Labcorp Holdings Inc. operate in?
Labcorp Holdings Inc. operates in the Healthcare sector, within the Diagnostics & Research industry. The Related Stocks section lists sector peers for comparison.
What does Labcorp Holdings Inc. do?
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market.
About Labcorp Holdings Inc. (LH) Stock
Labcorp Holdings Inc. (LH) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry. As of the latest update, Labcorp Holdings Inc. is trading at $317.95, down 2.19% on the day with a market capitalization of $25.8 billion. The financial health score for LH is 59/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for LH stock.
LH Stock Analysis & Key Metrics
On PreMarketPrice, you can track Labcorp Holdings Inc. (LH) across multiple dimensions:
- Pre-market price & movement: Real-time LH stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for LH with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Labcorp Holdings Inc. across multiple reporting periods.
- Financial health score: A composite score of 59/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for LH.
- Sector peers: Compare LH against 6 other healthcare stocks on key financial metrics.
Is LH a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Labcorp Holdings Inc. (LH) as an investment. The financial health score of 59/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Labcorp Holdings Inc. (LH) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.